Abstract
We aimed to identify genetic variants associated with heart failure by using a rat model of the human disease. We performed invasive cardiac hemodynamic measurements in F2 crosses between spontaneously hypertensive heart failure (SHHF) rats and reference strains. We combined linkage analyses with genome-wide expression profiling and identified Ephx2 as a heart failure susceptibility gene in SHHF rats. Specifically, we found that cis variation at Ephx2 segregated with heart failure and with increased transcript expression, protein expression and enzyme activity, leading to a more rapid hydrolysis of cardioprotective epoxyeicosatrienoic acids. To confirm our results, we tested the role of Ephx2 in heart failure using knockout mice. Ephx2 gene ablation protected from pressure overload–induced heart failure and cardiac arrhythmias. We further demonstrated differential regulation of EPHX2 in human heart failure, suggesting a cross-species role for Ephx2 in this complex disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Accessions
GenBank/EMBL/DDBJ
References
Kannel, W.B. & Belanger, A.J. The epidemiology of heart failure. Am. Heart J. 121, 951–957 (1991).
Levy, D. et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397–1402 (2002).
Owan, T.E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251–259 (2006).
Chien, K.R. Genomic circuits and the integrative biology of cardiac diseases. Nature 407, 227–232 (2000).
Kostis, J.B. et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. J. Am. Med. Assoc. 278, 212–216 (1997).
Dahlof, B. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281–1285 (1991).
Lee, D.S. et al. Association of parental heart failure with risk of heart failure in offspring. N. Engl. J. Med. 355, 138–147 (2006).
McCune, S., Baker, P.B. & Stills, F.H. SHHF/Mcc-cp rat: model of obesity, non-insulin-dependent diabetes, and congestive heart failure. Ilar News 32, 23–27 (1990).
Sack, M.N. et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94, 2837–2842 (1996).
Heyen, J.R. et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am. J. Physiol. Heart Circ. Physiol. 283, H1775–H1784 (2002).
Holycross, B.J., Summers, B.M., Dunn, R.B. & McCune, S.A. Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. Am. J. Physiol. 273, H228–H233 (1997).
Bergman, M.R., Kao, R.H., McCune, S.A. & Holycross, B.J. Myocardial tumor necrosis factor-α secretion in hypertensive and heart failure-prone rats. Am. J. Physiol. 277, H543–H550 (1999).
Brem, R.B., Yvert, G., Clinton, R. & Kruglyak, L. Genetic dissection of transcriptional regulation in budding yeast. Science 296, 752–755 (2002).
Grupe, A. et al. In silico mapping of complex disease-related traits in mice. Science 292, 1915–1918 (2001).
Karp, C.L. et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1, 221–226 (2000).
Klose, J. et al. Genetic analysis of the mouse brain proteome. Nat. Genet. 30, 385–393 (2002).
Liao, G. et al. In silico genetics: identification of a functional element regulating H2-Eα gene expression. Science 306, 690–695 (2004).
Monks, S.A. et al. Genetic inheritance of gene expression in human cell lines. Am. J. Hum. Genet. 75, 1094–1105 (2004).
Morley, M. et al. Genetic analysis of genome-wide variation in human gene expression. Nature 430, 743–747 (2004).
Schadt, E.E. et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 422, 297–302 (2003).
Bystrykh, L. et al. Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat. Genet. 37, 225–232 (2005).
Chesler, E.J. et al. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat. Genet. 37, 233–242 (2005).
Hübner, N. et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat. Genet. 37, 243–253 (2005).
Reffelmann, T. & Kloner, R.A. Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res. Cardiol. 98, 275–284 (2003).
Imig, J.D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc. Drug Rev. 24, 169–188 (2006).
Solomon, S.D. et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112, 3738–3744 (2005).
Molkentin, J.D. & Dorn, G.W., II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391–426 (2001).
Frey, N., Katus, H.A., Olson, E.N. & Hill, J.A. Hypertrophy of the heart: a new therapeutic target? Circulation 109, 1580–1589 (2004).
Seidman, J.G. & Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104, 557–567 (2001).
Watkins, H. & Farrall, M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat. Rev. Genet. 7, 163–173 (2006).
Pfeffer, M.A. & Frohlich, E.D. Hemodynamic and myocardial function in young and old normotensive and spontaneously hypertensive rats. Circ. Res. 32 (suppl. 1), 28–38 (1973).
Cingolani, O.H., Yang, X.P., Cavasin, M.A. & Carretero, O.A. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 41, 249–254 (2003).
Shorofsky, S.R. et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ. Res. 84, 424–434 (1999).
Slama, M., Ahn, J., Varagic, J., Susic, D. & Frohlich, E.D. Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: effects of hypertension and age. Am. J. Physiol. Heart Circ. Physiol. 286, H181–H185 (2004).
Hunt, S.A. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 38, 2101–2113 (2001).
Hammock, B.D., Ratcliff, M. & Schooley, D.A. Hydration of an 18O epoxide by a cytosolic epoxide hydrolase from mouse liver. Life Sci. 27, 1635–1641 (1980).
Imig, J.D., Zhao, X., Capdevila, J.H., Morisseau, C. & Hammock, B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690–694 (2002).
Spector, A.A., Fang, X., Snyder, G.D. & Weintraub, N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43, 55–90 (2004).
Spiecker, M. & Liao, J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 433, 413–420 (2005).
Seubert, J.M. et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99, 442–450 (2006).
Frantz, S. et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc. Res. 57, 749–756 (2003).
Ai, D. et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. USA 104, 9018–9023 (2007).
Luria, A. et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282, 2891–2898 (2007).
Xu, D. et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA 103, 18733–18738 (2006).
Seubert, J. et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ. Res. 95, 506–514 (2004).
Baan, J. et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 70, 812–823 (1984).
Gross, V. et al. Autonomic nervous system and blood pressure regulation in RGS2-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R1134–R1142 (2005).
Baurand, A. et al. β-catenin downregulation is required for adaptive cardiac remodeling. Circ. Res. 100, 1353–1362 (2007).
Fiala-Beer, E., Lee, A.C. & Murray, M. Regulation of the rat CYP4A2 gene promoter by c-Jun and octamer binding protein-1. Int. J. Biochem. Cell Biol. 39, 1235–1247 (2007).
Acknowledgements
We thank A. Müller, H. Kistel, A. Schiche, J. Mothes, J. Meisel, M. Rothe and M. Taube for technical assistance. We acknowledge funding to N.H. from the German Ministry for Science and Education (National Genome Research Network) and support through STAR and EURATools (European Commission contract LSHG-CT-2004-005235 and LSHG-CT-2005-019015); to F.C.L. and W.-H.S. from the Deutsche Forschungsgemeinschaft; to B.D.H. from US National Institute of Environmental Health Sciences grant R37 ES02710; and to S.A.C. from the British Heart Foundation and the UK Department of Health.
Author information
Authors and Affiliations
Contributions
N.H. and J.M. developed the project. N.H. directed the project. J.F., S.P., C.G., C.S., H.M., G.P., K.S., S.A.C. and W.-H.S. performed genetic and biochemical analysis. J.M., A.H., R.F., A.S., V.G., R.D. and F.C.L. performed and analyzed physiological experiments. M.H., H.S., O.H., M.V. and K.R. carried out statistical analysis. B.D.H., S.M.W., K.L. and S.A.C. contributed materials. N.H. wrote the paper with J.M., J.F. and F.C.L.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Note, Supplementary Figures 1–7, Supplementary Tables 1–3, Supplementary Methods (PDF 387 kb)
Rights and permissions
About this article
Cite this article
Monti, J., Fischer, J., Paskas, S. et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40, 529–537 (2008). https://doi.org/10.1038/ng.129
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.129
This article is cited by
-
Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics
Phenomics (2023)
-
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Signal Transduction and Targeted Therapy (2021)
-
Ephx2-gene deletion affects acetylcholine-induced relaxation in angiotensin-II infused mice: role of nitric oxide and CYP-epoxygenases
Molecular and Cellular Biochemistry (2020)
-
Stress, Genes, and Hypertension. Contribution of the ISIAH Rat Strain Study
Current Hypertension Reports (2018)
-
eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women
Archives of Gynecology and Obstetrics (2014)